Notably, a subgroup of patients with RB clinical outcome carried the DNMT3A A/C genotype, expressed similar levels of genes in the T cell enriched module, yet had reduced expression of genes in the B cell enriched module. This evidence concerns the gene DNMT3A and retinoblastoma.